Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.

Nadkarni A, Kalsekar I, You M, Forbes R, Hebden T.

Clinicoecon Outcomes Res. 2013;5:49-57. doi: 10.2147/CEOR.S36526. Epub 2013 Jan 20.

2.

Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.

Halpern R, Nadkarni A, Kalsekar I, Nguyen H, Song R, Baker RA, Nelson JC.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):933-45. doi: 10.1345/aph.1R622. Epub 2013 May 28.

PMID:
23715066
3.

Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.

Bergeson JG, Kalsekar I, Jing Y, You M, Forbes RA, Hebden T.

Am Health Drug Benefits. 2012 Sep;5(6):379-86.

4.

Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.

Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.

J Med Econ. 2011;14(6):777-86. doi: 10.3111/13696998.2011.625066. Epub 2011 Sep 29.

PMID:
21954966
5.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

6.

Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.

Kim E, Maclean R, Ammerman D, Jing Y, Pikalov A, You M, Van-Tran Q, L'Italien G.

Clin Ther. 2009 Apr;31(4):836-48. doi: 10.1016/j.clinthera.2009.04.022.

PMID:
19446157
7.

Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.

Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G.

Ann Pharmacother. 2012 May;46(5):642-9. doi: 10.1345/aph.1Q326. Epub 2012 May 1.

PMID:
22550279
8.
9.

Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.

Jing Y, Kalsekar I, Curkendall SM, Carls GS, Bagalman E, Forbes RA, Hebden T, Thase ME.

Clin Ther. 2011 Sep;33(9):1246-57. doi: 10.1016/j.clinthera.2011.07.015. Epub 2011 Aug 12.

PMID:
21840058
10.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
12.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients..

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

13.

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.

Gianfrancesco F, White R, Wang RH, Nasrallah HA.

J Clin Psychopharmacol. 2003 Aug;23(4):328-35.

PMID:
12920407
15.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
16.

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.

Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

J Med Econ. 2011;14(4):508-15. doi: 10.3111/13696998.2011.593602. Epub 2011 Jun 21.

PMID:
21692605
17.

Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.

Aparasu RR, Jano E, Johnson ML, Chen H.

Am J Geriatr Pharmacother. 2008 Oct;6(4):198-204. doi: 10.1016/j.amjopharm.2008.10.003.

PMID:
19028375
18.

Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States.

Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, Ford DE.

Arch Gen Psychiatry. 2003 Feb;60(2):121-8.

PMID:
12578429
19.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
20.

Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.

Lage MJ, Gross GN, Brewster C, Spalitto A.

Adv Ther. 2009 Aug;26(8):762-75. doi: 10.1007/s12325-009-0056-z. Epub 2009 Aug 8.

PMID:
19669630

Supplemental Content

Support Center